Misplaced Alarmism: A Critical Analysis of a First North American "Severe" H5N1 Case Report, Editorial, and Media Coverage in a 13-Year Old Girl, British Columbia, Canada
Alarmism and sensationalism are alive and well as a person with comorbidities survives intubation and three plasma exchanges. The case study, the Editorial and Medpage Today suffer serious problems.
We request that you share this on social media and email lists to help counter and quell panic - PR from this first serious H5N1 case in North America.
This critique evaluates the Canadian H5N1 case study published in the New England Journal of Medicine (NEJM), its accompanying editorial, and the subsequent media coverage by MedPage Today (MPT). The analysis identifies significant issues, including overinterpretation of mutations as markers of human adaptation, lack of transparency in data sharing, and the use of an aggressive, unvalidated antiviral regimen that likely introduced iatrogenic risks. The editorial compounds these shortcomings by amplifying speculative conclusions without addressing critical gaps in the study, such as the absence of publicly available genomic data and contextual epidemiological comparisons. MPT further perpetuates alarmism through uncritical reporting, focusing on fear-driven narratives rather than fostering an informed understanding of the case. The critique highlights the risks of sensationalism in public health reporting and calls for greater rigor, accountability, and balance in scientific research, editorial oversight, and medical journalism to ensure effective communication of emerging health threats.
Overtreatment
Doctors’ unconventional use of three antivirals (oseltamivir, amantadine, baloxavir) and daily plasma exchange for three days in a 13-year girl from British Columbia, Canada raises questions.
Acute kidney injury, thrombocytopenia, leukopenia, and systemic instability are consistent with possible side effects of the antivirals used and the systemic effects of cytokine storm.
Pharmacokinetic complexities introduced by renal impairment, CRRT, and plasma exchange logically support the possibility of iatrogenic effects.
Aggressive interventions risk being interpreted as standard practice, potentially leading to unnecessary or harmful treatments in future cases.
Hyperbaric oxygen therapy would have prevented the need for intubation.
Overinterpretation of Results
Mutations (E627K, E186D, Q222H) in the viral sequence from the girl are described as “worrisome,” but their low allele frequencies (28%-52%) among the lineages suggest they may not be significant in general human adaptation or transmissibility.
Lack of clarity on whether these mutations were part of the initial viral strain or emerged during replication in the host.
The study generalizes the threat based on a single severe case, ignoring the disparity with mild U.S. cases.
Failure to Contextualize Severity
The Canadian case is presented in isolation without addressing why it differs from the 46 U.S. cases involving the same clade, which were predominantly mild and resulted in no deaths.
Factors such as her serious comorbidities, host immunity, exposure route, or intervention timing are not explored.
Iatrogenic interactions among antivirals were not considered (see full critical review, below)
Lack of Transparency
Genomic sequences of the virus were not made publicly available for independent verification (GISAID data “under review”)
Metadata on the patient’s exposure history and community transmission risks are missing.
Surveillance gaps in the NEJM study are mirrored by similar deficiencies and uncriticality in MedPage Today’s reporting.
Selective Critique of Data Gaps
The editorial critiques metadata deficiencies in animal sequencing but fails to address similar gaps in the human case study.
No acknowledgment of how these omissions undermine the ability to draw broader conclusions.
Sensationalism in Reporting
MedPage Today amplifies speculative risks from the study and editorial without critically assessing the evidence.
Fear-driven language, such as emphasizing the severity of mutations and the “worrisome” nature of findings, dominates the narrative.
Missed opportunities to educate the public on the broader epidemiological context and rarity of severe cases.
Neglect of Comparative Context
No exploration of why North American cases have generally been mild, despite global concerns about H5N1’s alleged high case fatality rate.
Potential mitigating factors, such as improved surveillance and medical interventions, are ignored.
Encouragement of Panic-Driven Policies
Speculative conclusions about human-to-human transmission risk could lead to reactionary public health measures, such as unnecessary vaccine rollouts or resource misallocation.
Alarmism may erode public trust and create resistance to future messaging about genuine health threats.
A recent case report on a hospitalized H5N1 avian influenza case in a Canadian teenager has sparked widespread discussion, with much of the public narrative shaped by a MedPage Today article and an editorial published in The New England Journal of Medicine (NEJM). The case, which involved a 13-year-old girl given intensive care measures including extracorporeal membrane oxygenation (ECMO) and an aggressive multi-drug antiviral regimen, has been described as a significant example of the emerging threat posed by H5N1. However, the accompanying NEJM editorial and MedPage Today’s coverage have amplified alarm without offering sufficient context or critical analysis.
The possibility of iatrogenic interactions of these treatments was not considered. Close analysis reveals the concurrent use of three antivirals—oseltamivir, amantadine, and baloxavir—could have induced clinical worsening by contributing to drug accumulation, neurotoxicity, immune suppression, or subtherapeutic dosing during plasma exchange, exacerbating systemic instability and organ dysfunction (we provide a full critical review at the end of this article).
The MedPage Today article, in particular, presents a narrative that prioritizes sensationalism over scientific rigor, emphasizing fear-inducing aspects of the case while neglecting critical counterpoints and uncertainties. This approach not only misinforms the public but also risks fostering panic-driven public health responses that are neither evidence-based nor proportionate to the actual threat. Furthermore, the article fails to interrogate critical gaps in the original study and accompanying editorial, such as the significance of observed mutations, the appropriateness of the treatment strategy, and the broader epidemiological context.
This analysis will explore the shortcomings of the study, the Editorial, and the MedPage Today article, situating them within the broader pattern of fear-driven medical reporting that prioritizes attention-grabbing headlines over disseminating accurate, balanced, and non-sensationalized information. By examining the specific ways the article falls short—such as its uncritical amplification of speculative conclusions, neglect of vital comparative context, and failure to promote public understanding—it becomes clear that the coverage does more to stoke public anxiety than enhance public knowledge. Addressing these issues is essential for restoring trust in medical journalism and ensuring that emerging public health threats are met with clarity, transparency, and evidence-based action.
Overstating the Conclusions and Significance
While a compelling clinical account, the NEJM study on the severe H5N1 case in a Canadian teenager overstates its conclusions and raises several critical concerns that are not adequately addressed. These issues highlight gaps in the study's methodology, interpretation, and broader implications.
A significant issue in the study is the overemphasis on observed mutations as definitive markers of increased human adaptation and virulence. The identification of E627K in the polymerase basic 2 (PB2) gene and E186D and Q222H in the hemagglutinin (HA) gene is presented as “worrisome,” implying that these mutations represent an alarming step toward human-to-human transmission. However, the study fails to critically assess the low allele frequencies of these mutations, which range from 28% to 52%. These figures suggest that the mutations may not have been present in the original infecting strain and could have emerged during the course of the infection, which has now resolved. The study does not address this ambiguity, leaving its conclusions about the role of these mutations speculative at best.
The study also generalizes the threat posed by the virus based on a single severe case. While the patient’s condition was indeed critical, the authors do not adequately explore why this case differs so dramatically from the overwhelmingly mild outcomes seen in U.S. cases involving the same H5N1 clade. For example, the 46 U.S. cases reported between March and October 2024 were characterized by mild symptoms, such as conjunctivitis and fever, only about 50% even had fever, and none led to hospitalizations for respiratory symptoms or deaths. The study does not discuss potential factors that could explain this disparity, such as differences in host immunity, the route of exposure, or the timing and nature of medical intervention. This omission weakens the study’s claim that the identified mutations indicate a broader public health risk.
Another area of concern is the lack of transparency regarding the viral genome sequence. While the study reports significant findings about mutations, it does not make the full genomic data publicly available for independent verification. This is a critical omission, particularly for a case with such far-reaching implications. By not releasing the genomic data, the study limits the ability of the broader scientific community to assess the validity of its claims and explore alternative interpretations of the findings.
The treatment approach described in the study also raises serious questions about medical overtreatment for hype. The combination of oseltamivir, amantadine, and baloxavir, along with plasma exchange, is unconventional and lacks clear justification. The study does not provide evidence to support the dramatic use of three plasma exchanges as a cytokine modulation strategy, nor does it explain why three antivirals were deemed necessary. The report of improved respiratory status and reduced viral load could easily be attributed to the natural progression of the illness rather than to the specific interventions used. By failing to evaluate the efficacy of these treatments critically, the study risks promoting an aggressive and potentially unnecessary therapeutic strategy.
This case is presented as the first report of a critically ill pediatric patient with H5N1 in North America. However, the uniqueness of the case (e.g., patient comorbidities like obesity and asthma) and the lack of comparable cases limit the generalizability of the findings to other settings or patient populations.
Furthermore, the study does not adequately address surveillance and epidemiological gaps. While it critiques the lack of metadata in animal sequencing, it fails to provide sufficient information about the patient’s exposure history or potential community-level transmission. This lack of detail limits the study’s ability to contribute to a broader understanding of the epidemiology of H5N1 in North America.
Overall, while the NEJM study offers valuable insights into a rare and severe case, it overstates the implications of its findings, omits critical contextual details, and leaves many questions unanswered. These shortcomings undermine the study’s credibility and contribute to a narrative of fear and urgency not fully justified by the evidence. A more cautious and balanced approach would better serve both the scientific community and the public.
Misattribution and Fear-Mongering in the Editorial
The editorial accompanying the NEJM study on the Canadian H5N1 case serves as a troubling example of how speculative and premature conclusions can amplify fear rather than foster a balanced understanding of emerging threats. While the editorial rightly emphasizes the importance of surveillance and preparedness, it overextends the implications of a single severe case. It fails to interrogate the uncertainties and gaps within the study it references.
A key issue with the editorial is its undue focus on mutations as evidence of an emerging threat. The authors emphasize the presence of E627K in the polymerase basic 2 (PB2) gene and E186D and Q222H in the hemagglutinin (HA) gene, presenting these as markers of human adaptation and potential human-to-human transmissibility. However, the editorial does not address the low allele frequencies of these mutations in the patient’s viral isolates—frequencies ranging from 28% to 52% that suggest the mutations may have emerged during the course of infection rather than being part of the original viral strain. The unusual simultaneous administration of antivirals was not accompanied by anticipation of iatrogenic effects; critical medical journalism would have caught that possibility. By failing to discuss these uncertainties, the editorial misrepresents the mutations as definitive indicators of an increased threat, misleading readers about the actual level of risk.
The editorial also extrapolates from this single case to suggest broader implications for public health. While the severity of the Canadian case is acknowledged, it is positioned as emblematic of the risks posed by H5N1, despite overwhelming evidence from U.S. cases to the contrary. The 46 U.S. cases linked to the same clade (2.3.4.4b) have been predominantly mild, with no deaths and minimal hospitalizations, even among those with confirmed viral infections. The editorial fails to explore why this Canadian case was an outlier, ignoring factors like host-specific responses, underlying health conditions, and potential differences in viral dynamics. This lack of context inflates the perceived threat, creating a disproportionate narrative to the evidence.
Another problematic aspect of the editorial is its critique of surveillance metadata. While it correctly notes deficiencies in animal genomic data, it neglects to address the similar lack of critical metadata in the human case study itself. For example, there is no detailed information about the patient’s exposure history, potential environmental sources, or any evidence of community transmission. The editorial’s failure to hold the referenced study to the same standard it applies to animal data undermines its credibility and suggests a selective approach to critiquing data gaps.
The editorial’s treatment of the treatment protocol is similarly flawed. It highlights the need for longer antiviral therapy and combination treatment strategies without critically examining whether the interventions used in the Canadian case were appropriate or effective. The aggressive use of three antivirals and plasma exchange is presented as necessary, yet there is no discussion of whether these measures were supported by evidence or if the patient’s recovery might have been due to the natural course of the disease. The editorial risks encouraging unnecessary or unproven interventions in future cases by uncritically endorsing this aggressive approach.
Finally, the editorial fails to strike a balance between vigilance and alarmism. While it calls for a measured approach to monitoring H5N1, its tone and emphasis on potential human-to-human transmission create a sense of imminent danger that is not justified by the available data. This fear-driven narrative could lead to reactionary public health measures, such as premature vaccine rollouts or excessive stockpiling of antivirals, diverting resources from more pressing issues. Moreover, the editorial does not provide actionable guidance for addressing the identified gaps in surveillance or data collection, leaving readers with heightened concern but no clear path forward.
In sum, the editorial amplifies speculative risks while neglecting critical uncertainties and disparities in the data. Its misattribution of significance to mutations, failure to contextualize the severity of the Canadian case, selective critique of data gaps, and uncritical endorsement of aggressive treatments all contribute to an inflated narrative of fear. This approach undermines the editorial’s stated goal of fostering preparedness and instead risks promoting policies and practices that are not grounded in evidence. A more measured and transparent discussion of the study’s findings would have better served both the scientific community and the public.
Fear Over Knowledge: A Critique of MedPage Today’s Coverage
The MedPage Today article on the Canadian H5N1 case exemplifies a journalistic failure to engage with scientific findings critically and instead opts to amplify fear through selective and uncritical reporting. While the article highlights the dramatic aspects of the case, such as the severity of the patient’s condition and the mutations identified in the virus, it lacks the critical analysis necessary to provide readers with an accurate and balanced understanding of the event. This approach prioritizes sensationalism over informing the public, contributing to a climate of unnecessary fear around H5N1.
A significant flaw in the article is its uncritical repetition of the NEJM study’s claims about mutations in the virus. The piece prominently features the presence of E627K in the PB2 gene and E186D and Q222H in the HA gene, emphasizing that these mutations are “worrisome” and associated with human adaptation. However, it fails to acknowledge the low allele frequencies (28%-52%) of these mutations, a key detail that raises doubts about their functional significance. By omitting this crucial nuance, the article leaves readers with the impression that these mutations definitively represent an increased threat of human-to-human transmission, an assertion unsupported by the data. This lack of scrutiny perpetuates the misattribution bias in the NEJM study and editorial.
The article also neglects to contextualize the rarity of such severe cases. While the Canadian teenager’s illness was critical, this case is an outlier compared to the 46 U.S. cases involving the same H5N1 clade (2.3.4.4b), which were predominantly mild, with no deaths and minimal hospitalizations. MedPage Today does not address this disparity or explore potential explanations, such as differences in host immunity, exposure routes, or early intervention. Instead, it presents the Canadian case in isolation, contributing to a distorted perception of the overall risk posed by H5N1. This failure to provide comparative context leaves readers uninformed about the broader epidemiological picture.
The reporting on the treatment strategy used in the Canadian case is similarly superficial. The article describes the use of three antivirals (oseltamivir, amantadine, and baloxavir) and plasma exchange but does not question the appropriateness or evidence base for these interventions. There is no discussion of whether these measures were experimental or necessary, nor any acknowledgment that the patient’s recovery might have been due to the natural progression of the disease rather than the aggressive treatment regimen. The article risks endorsing unproven or excessive therapeutic strategies without sufficient justification by failing to evaluate the described interventions critically.
Another significant oversight is the lack of transparency regarding the viral genome sequence. The NEJM study did not make this data publicly available, which is a critical omission given the potential significance of public health in the case. MedPage Today does not mention this nor critique the lack of detailed metadata about the patient’s exposure history and potential community transmission. Instead, the article focuses on amplifying speculative conclusions without addressing the gaps and uncertainties in the underlying data. This selective reporting undermines its credibility and contributes to a narrative of alarm rather than understanding.
The article also misses an opportunity to educate readers about the broader epidemiological context of H5N1. While it emphasizes the severity of the Canadian case, it does not explain that North American cases of H5N1 have generally been mild, with improved surveillance, early detection, and timely interventions likely playing significant roles. This failure to highlight the positive trends in H5N1 management leaves readers with an unbalanced view of the situation, focusing only on the potential dangers without considering mitigating factors.
Overall, the MedPage Today article amplifies fear while failing to engage critically with the scientific study it reports on. By uncritically repeating speculative claims, neglecting contextual details, and overlooking critical gaps in the data, the article sacrifices journalistic rigor in favor of sensationalism. Such reporting misinforms the public and risks promoting panic-driven responses that divert resources and attention from more pressing public health priorities. A more thoughtful and balanced approach would better serve readers and contribute to a more informed public discourse around emerging health threats.
Journalistic Responsibility and Ethical Concerns
Journalism, particularly in fields as consequential as public health, carries the weighty responsibility of fostering informed discourse. Medical journalism is uniquely positioned to bridge the gap between complex scientific findings and public understanding, and its credibility relies on providing balanced, accurate, and contextual reporting. Unfortunately, the MedPage Today article on the Canadian H5N1 case, alongside the NEJM editorial it references, falls short of these standards, raising significant ethical concerns.
By uncritically amplifying speculative conclusions from the NEJM study and editorial, the MedPage Today article neglects the journalist’s duty to assess the evidence in the proper context. Repeating claims about mutations and their alleged implications for human-to-human transmission without addressing the low allele frequencies or contextual uncertainties misleads the public. This failure is compounded by the lack of scrutiny regarding the aggressive treatment protocol, which is presented as necessary and effective despite insufficient supporting evidence. Journalistic rigor demands a more critical approach, one that questions the appropriateness of interventions and the validity of conclusions, especially in cases with such potentially broad implications.
The article also misses an opportunity to hold the NEJM study accountable for its omissions. Key details remain unaddressed, such as the lack of publicly available genomic data and the absence of comprehensive metadata about the patient’s exposure history. Instead of pushing for transparency and challenging the gaps in the study, MedPage Today opted instead to magnify its alarmist narrative, undermining public trust in both the media and the scientific institutions it reports on. This approach prioritizes sensationalism over accountability, contributing to a culture of fear that can erode public confidence in medical journalism.
The ethical implications of this approach are profound. Fear-driven narratives risk encouraging reactionary public health policies, such as unnecessary vaccine campaigns or excessive resource allocation to a threat that may be overstated. Such policies can divert attention and funding from more pressing health concerns, ultimately harming the public these efforts aim to protect. Furthermore, sensationalism in medical reporting contributes to the broader issue of public desensitization; repeated alarmist coverage may lead to skepticism or apathy, even when genuine threats arise.
Medical journalism must strive for accuracy, balance, and transparency. By failing to meet these standards, the MedPage Today article not only misinforms the public but also undermines the credibility of journalism as a whole. A more ethical approach would involve critically engaging with the evidence, addressing uncertainties, and emphasizing informed analysis over fear.
Conclusion
The reporting on the Canadian H5N1 case, from the NEJM study to the accompanying editorial and the MedPage Today article, exemplifies how gaps in critical analysis and transparency can distort public understanding of emerging health threats. Each element of this narrative—from the overemphasis on mutations to the uncritical presentation of treatment strategies—amplifies fear without sufficient evidence to justify such alarm. This unbalanced approach misrepresents the science and risks promoting reactionary public health responses that could divert resources from more pressing needs.
Transparency, contextual accuracy, and skepticism are foundational to both scientific research and medical journalism. The NEJM study’s failure to release genomic data and provide comprehensive metadata undermines its conclusions, while the editorial compounds this issue by overstating speculative risks without interrogating the study’s limitations. The MedPage Today article, by amplifying these flaws and failing to provide critical context, serves as an unfortunate example of how fear can overshadow knowledge in medical reporting.
Moving forward, it is essential for all stakeholders—researchers, journalists, public health professionals, and the public—to prioritize clarity, balance, and evidence-based communication. Without these principles, the public discourse on emerging health threats will remain vulnerable to misinformation and fear-mongering, to the detriment of public trust and effective health policy.
Recommendations
The shortcomings in the reporting on the Canadian H5N1 case offer an opportunity for reflection and improvement across multiple sectors. To prevent similar issues in the future, the following recommendations should be adopted:
For Researchers: Transparency in data sharing is critical. The genomic sequences and metadata associated with significant cases must be made publicly available to allow independent verification and broader scientific engagement. Additionally, conclusions should be carefully contextualized, acknowledging uncertainties and avoiding speculative claims that could mislead public discourse.
For Journalists: Medical journalism must prioritize critical evaluation over sensationalism. Reporters should question the validity of conclusions presented in scientific studies, investigate gaps or omissions in the data, and provide readers with a balanced understanding of the evidence. Sensational narratives may attract attention, but they ultimately undermine trust and public understanding.
For Public Health Professionals: Communication strategies must balance vigilance with reassurance, emphasizing evidence-based guidance over speculative risks. Public health policies should reflect measured, proportionate responses to emerging threats, avoiding reactionary measures driven by fear. Professionals should also advocate for greater transparency and accountability in both research and reporting.
For the Public: Media literacy is an essential tool for navigating the modern information landscape. Readers should approach alarmist narratives with skepticism, seek additional sources of information, and advocate for transparency and accountability in journalism. By demanding higher standards from both journalists and researchers, the public can help ensure that critical health issues are addressed thoughtfully and effectively.
Adopting these recommendations will not only improve the quality of public discourse on health threats but also enhance trust in the institutions responsible for managing them. A commitment to accuracy, balance, and transparency is essential for fostering an informed, resilient, and empowered public.
In sum, this case and its coverage reveal significant flaws in the intersection of science, media, and public health. Overinterpretation of data, sensationalist reporting, and selective critique of gaps undermine the credibility of all parties involved. Addressing these issues will require systemic changes, including stricter standards for scientific transparency, more critical oversight in medical journalism, and a renewed focus on educating the public with balanced, evidence-based narratives. Without these reforms, public trust in both science and health policy will continue to erode, leaving society ill-prepared to respond effectively to genuine threats.
Antiviral Iatrogenicity and Clinical Worsening
The aggressive use of three antivirals—oseltamivir, amantadine, and baloxavir—in the treatment of the critically ill Canadian teenager with H5N1 raises significant concerns about iatrogenic effects, particularly given the overlapping challenges of plasma exchange and continuous renal replacement therapy (CRRT). A detailed schedule-aware analysis of antiviral administration and its interaction with the patient’s clinical trajectory reveals how the timing, pharmacokinetics, and potential side effects of these drugs may have contributed to her condition.
Antiviral Administration Schedule
Oseltamivir (Tamiflu):
Initiated on November 8 after confirmation of influenza A with a low Ct value (27.1), suggesting a high viral load.
Likely continued throughout the treatment course but not specified when it was discontinued.
As a neuraminidase inhibitor, its goal was to suppress viral replication in later stages of the viral lifecycle.
Amantadine (Gocovri):
Introduced on November 9, likely as a complementary antiviral targeting the M2 ion channel.
Continued alongside oseltamivir, despite widespread resistance among H5N1 strains, raising questions about its efficacy in this case.
Baloxavir (Xofluza):
Administered starting November 11, three days after oseltamivir and two days after amantadine.
Likely given in an attempt to inhibit viral replication at an earlier stage of the lifecycle through its action as a cap-dependent endonuclease inhibitor.
Plasma Exchange:
Performed daily from November 14 to November 16 to manage cytokine storm and systemic instability, introducing significant pharmacokinetic complexities by removing plasma-bound and circulating antivirals.
Plasma Exchange and Pharmacokinetics
Plasma exchange involves replacing the patient’s plasma, effectively removing a portion of drugs present in the bloodstream. This has profound implications for the antivirals used:
Oseltamivir: While its active metabolite, oseltamivir carboxylate, is minimally protein-bound (~3%), its clearance primarily depends on renal function. Plasma exchange likely had a limited direct impact on its levels, but concurrent CRRT and renal dysfunction posed risks of both subtherapeutic dosing (if removed) and accumulation (if clearance was insufficient). Either scenario could exacerbate systemic instability.
Amantadine: Moderately protein-bound (~67%) and renally excreted, amantadine is highly susceptible to removal by plasma exchange. Given the patient’s acute kidney injury and need for CRRT, maintaining therapeutic levels would have required precise re-dosing. Failure to adjust doses could lead to either insufficient viral suppression or toxic accumulation, increasing the risk of neurotoxicity, including confusion, agitation, and seizures.
Baloxavir: With very high plasma protein binding (~93-94%), baloxavir was likely significantly removed during plasma exchange. Its therapeutic efficacy depends on maintaining effective plasma concentrations, and without re-dosing, its antiviral activity could have been substantially reduced, risking viral persistence and resistance.
Supplementary Table 1 shows significant deviations in laboratory values (e.g., elevated CRP, low WBC, and platelets). Still, the discussion does not clearly connect these to either the disease process or possible treatment-related side effects. This omission limits the study’s ability to address potential iatrogenic factors comprehensively.
The study does not explore whether triple antiviral therapy, used in the absence of reduced susceptibility, provided incremental benefits compared to standard care. This omission leaves a gap in evaluating the risk-benefit ratio of such an aggressive approach.
Antiviral Iatrogenicity and Clinical Worsening: A Schedule-Aware Analysis
The aggressive use of three antivirals—oseltamivir, amantadine, and baloxavir—in the treatment of the critically ill Canadian teenager with H5N1 raises significant concerns about iatrogenic effects, particularly given the overlapping challenges of plasma exchange and continuous renal replacement therapy (CRRT). A detailed schedule-aware analysis of antiviral administration and its interaction with the patient’s clinical trajectory reveals how the timing, pharmacokinetics, and potential side effects of these drugs may have contributed to her condition.
Antiviral Administration Schedule
Oseltamivir (Tamiflu):
Initiated on November 8 after confirmation of influenza A with a low Ct value (27.1), suggesting a high viral load.
Likely continued throughout the treatment course but not specified when it was discontinued.
As a neuraminidase inhibitor, its goal was to suppress viral replication in later stages of the viral lifecycle.
Amantadine (Gocovri):
Introduced on November 9, likely as a complementary antiviral targeting the M2 ion channel.
Continued alongside oseltamivir, despite widespread resistance among H5N1 strains, raising questions about its efficacy in this case.
Baloxavir (Xofluza):
Administered starting November 11, three days after oseltamivir and two days after amantadine.
Likely given in an attempt to inhibit viral replication at an earlier stage of the lifecycle through its action as a cap-dependent endonuclease inhibitor.
Plasma Exchange:
Performed daily from November 14 to November 16 to manage cytokine storm and systemic instability, introducing significant pharmacokinetic complexities by removing plasma-bound and circulating antivirals.
Plasma Exchange and Pharmacokinetics
Plasma exchange involves replacing the patient’s plasma, effectively removing a portion of drugs present in the bloodstream. This has profound implications for the antivirals used:
Oseltamivir: While its active metabolite, oseltamivir carboxylate, is minimally protein-bound (~3%), its clearance primarily depends on renal function. Plasma exchange likely had a limited direct impact on its levels, but concurrent CRRT and renal dysfunction posed risks of both subtherapeutic dosing (if removed) and accumulation (if clearance was insufficient). Either scenario could exacerbate systemic instability.
Amantadine: Moderately protein-bound (~67%) and renally excreted, amantadine is highly susceptible to removal by plasma exchange. Given the patient’s acute kidney injury and need for CRRT, maintaining therapeutic levels would have required precise re-dosing. Failure to adjust doses could lead to either insufficient viral suppression or toxic accumulation, increasing the risk of neurotoxicity, including confusion, agitation, and seizures.
Baloxavir: With very high plasma protein binding (~93-94%), baloxavir was likely significantly removed during plasma exchange. Its therapeutic efficacy depends on maintaining effective plasma concentrations, and without re-dosing, its antiviral activity could have been substantially reduced, risking viral persistence and resistance.
Potential Iatrogenic Contributions to Clinical Worsening
The combination of antivirals and systemic therapies may have inadvertently worsened the patient’s condition in several ways:
Renal Overload:
Both oseltamivir and amantadine are renally excreted, and the patient’s acute kidney injury and CRRT complicated their pharmacokinetics. Plasma exchange might have reduced drug levels, requiring higher doses to maintain efficacy, but this also increased the risk of accumulation and toxicity.
Neurotoxicity:
Amantadine is particularly associated with central nervous system (CNS) side effects, including hallucinations, confusion, and agitation, especially in the context of impaired renal clearance. Although the patient was intubated and sedated, neurotoxicity could have contributed to systemic instability.
Hematologic Effects:
The patient’s thrombocytopenia and leukopenia could have been exacerbated by antivirals. Amantadine has been linked to rare cases of thrombocytopenia, and baloxavir’s immune-modulating effects may have influenced leukocyte turnover, compounding immune suppression and increasing vulnerability to secondary complications.
Resistance and Subtherapeutic Dosing:
Plasma exchange likely removed significant amounts of baloxavir, and possibly amantadine, reducing their efficacy. Subtherapeutic levels can promote viral resistance, prolonging the infection and contributing to systemic inflammation. The absence of evidence supporting the combination of these three antivirals raises further concerns about their additive efficacy or safety.
Immune Dysregulation:
The overlapping mechanisms of these antivirals may have interacted unpredictably with the patient’s immune system. Baloxavir’s rapid reduction in viral replication could blunt adaptive immune responses, while plasma exchange further altered cytokine dynamics. This interaction may have amplified systemic instability rather than resolving it.
GI and Systemic Symptoms:
Nausea, vomiting, and diarrhea, common side effects of oseltamivir and baloxavir, could exacerbate dehydration and electrolyte imbalances, further destabilizing the patient.
Clinical Implications
The timing of plasma exchange, initiated six days after the first antiviral (oseltamivir) and three days after the last antiviral (baloxavir), added a layer of complexity that may have disrupted the intended pharmacologic effects. Maintaining therapeutic antiviral levels while managing renal dysfunction and systemic instability required exceptional pharmacologic oversight, which the study does not detail. The concurrent use of plasma exchange and CRRT likely reduced circulating drug levels, necessitating frequent dose adjustments or re-dosing to sustain antiviral activity.
The absence of established clinical evidence for combining these three antivirals, coupled with the pharmacokinetic disruptions caused by plasma exchange and CRRT, underscores the high risk of iatrogenic complications. While the patient’s recovery is commendable, it remains unclear to what extent the antiviral regimen contributed to her improvement versus prolonging her systemic instability.
Jaseem, A, et al., Critical Illness in an Adolescent with Influenza A(H5N1) Virus Infection NEJM https://www.nejm.org/doi/full/10.1056/NEJMc2415890
I keep thinking how different everything would be if doctors would use intravenous ascorbate drug and ozone to treat patients with severe viral infections in hospital.
And, we must always ask: Has she received the mRNA jabs? Almost certainly YES for Canada. With the Igg4 class switching, she was in a dangerous position to start with, as, I fear, are most jabbed folks.